Clinical Trial Update: Expanded Access Program With Nivolumab to Treat Melanoma

View source ↗

Summary

Expanded access program for nivolumab in melanoma has ended (no longer available).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Stage III (Unresectable) or Stage IV Advanced Melanoma | Status: NO_LONGER_AVAILABLE